Compare RVPH & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVPH | SCWO |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Environmental Services |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 72.8M |
| IPO Year | N/A | N/A |
| Metric | RVPH | SCWO |
|---|---|---|
| Price | $0.66 | $0.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.33 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 1.1M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,910,340.00 |
| Revenue This Year | N/A | $5,945.19 |
| Revenue Next Year | N/A | $106.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 508.52 |
| 52 Week Low | $0.25 | $0.16 |
| 52 Week High | $2.95 | $1.09 |
| Indicator | RVPH | SCWO |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 45.40 |
| Support Level | $0.60 | $0.26 |
| Resistance Level | $0.77 | $0.29 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 61.01 | 47.40 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.